HighTower Advisors’s Summit Therapeutics SMMT Stock Holding History

HighTower Advisors’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-10,758	Closed	-$222K	–	3930
2025 Q3	$222K	Sell	10,758 -28,623	-73%	-$694K	﹤0.01%	3282
2025 Q2	$838K	Buy	39,381 +184	+0.5%	+$4.2K	﹤0.01%	2127
2025 Q1	$756K	Sell	39,197 -120	-0.3%	-$2.41K	﹤0.01%	2160
2024 Q4	$702K	Buy	39,317 +160	+0.4%	+$3.1K	﹤0.01%	2222
2024 Q3	$857K	Buy	39,157 +107	+0.3%	+$1.5K	﹤0.01%	2020
2024 Q2	$305K	Sell	39,050 -25,000	-39%	-$135K	﹤0.01%	2699
2024 Q1	$265K	Buy	64,050 +52,100	+436%	+$207K	﹤0.01%	2777
2023 Q4	$31K	Buy	+11,950	New	+$24.6K	﹤0.01%	3358

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

PCMH

Polymer Capital Management (HK) Hong Kong $1.98B AUM 210.13% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

HighTower Advisors's SMMT Position: Q4 2025 in Review

HighTower Advisors sold out of Summit Therapeutics (SMMT) in Q4 2025, closing a stake of 10,758 shares — an estimated $222K sold.

HighTower Advisors first reported a position in SMMT in Q4 2023 and held it in 8 quarters. The position peaked at $857K in Q3 2024. 206 funds tracked by Wall St. Rank hold SMMT as of Q4 2025.

HighTower Advisors reported no remaining Summit Therapeutics position as of Q4 2025 after selling out during the quarter.
HighTower Advisors sold 10,758 Summit Therapeutics shares in Q4 2025, an estimated $222K.
HighTower Advisors first reported a position in Summit Therapeutics in Q4 2023 and held it in 8 quarters.
HighTower Advisors's Summit Therapeutics position peaked at $857K in Q3 2024.
206 funds tracked by Wall St. Rank held Summit Therapeutics as of Q4 2025.

Based on HighTower Advisors's 13F filing for Q4 2025, filed 6 Feb 2026.